FDA Approves DAPAGLIFLOZIN — Teva Pharmaceuticals, Inc.

# FDA Approves Generic Dapagliflozin; Teva Pharmaceuticals Enters Competitive SGLT2 Inhibitor Market Teva Pharmaceuticals, Inc. received FDA approval for its generic dapagliflozin oral formulation (ANDA211541) on April 6, 2026, positioning the company to capture market share in the increasingly competitive SGLT2 inhibitor segment used for diabetes and heart failure treatment. The approval is expected to increase price competition and expand patient access to the widely prescribed diabetes medication.